KALV

KalVista Pharmaceuticals, Inc. (KALV) | Rumor.io

KalVista Pharmaceuticals

KALV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)97%

Price to earnings ratio-7.32

Market capitalization1.4B

Earnings per share-3.94

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KALV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 1

KalVista Pharmaceuticals, Inc. (KALV) received a $1.9 billion cash buyout from Chiesi, an Italian private biotech company.
As of year-end 2025, KALV had $300.2 million in cash and equivalents, with $338.086 million in total liabilities, and generated $49.1 million in sales from its oral treatment for hereditary angioedema (HAE) attacks.
KALV's drug EKTERLY has a list price of $16,720 per pill and has shown rapid adoption, with 1,702 patient start forms received in the US from launch through February 2025.

Generated by AI

Sentiment

Of the messages about KALV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	60% -6.67	98.85% +3.34	90.02% -7.16
Bearish	100%	40% +6.67	1.15% -3.34	9.98% +7.16

Bullish· Apr 30

KalVista Pharma's Ekterly has already captured 20% of the HAE market in its first year of launch, setting the stage for strong earnings.
The acquisition by Chiesi Group at a 40% premium removes uncertainty around the pipeline, providing shareholders with a clean cash exit.
The biotech sector is strong, with KalVista Pharma experiencing a significant jump in volume and institutional accumulation following the acquisition.

Bearish· Jul 7

KalVista Pharmaceuticals' ($KALV) approval may be short-lived, as the stock's past performance after PDUFA post-approval suggests a potential decline.
The company's recent FDA approval may not translate to significant gains, as the stock's price movement is currently underwhelming expectations.
The stock's history of "pump and dump" schemes and failed short squeezes may indicate a lack of fundamental value, making it a potentially weak investment opportunity.

Generated by AI

Topics

Of the messages about KALV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	45.31%
Announcements	—	100%	100%	9.22%
Controversies	—	0%	0%	0.07%
Earnings	—	0%	0%	0.23%
Macro	—	0%	0%	44.78%
Technical Analysis	—	0%	0%	0.38%

Announcements· Apr 29

Chiesi Group is acquiring KalVista Pharmaceuticals, Inc. (KALV) for approximately $1.9 billion, or $27 per share in cash.
The acquisition is expected to close in Q3 2026 and will result in the end of public trading for KALV, with existing stock options and RSUs to be cashed out.
The deal will add KalVista's oral HAE therapy, EKTERLY, to Chiesi's global rare disease portfolio, expanding its presence in the rare disease market.

Technical Analysis· Feb 10

A bullish flag pattern is forming in $KALV.
$KALV has triggered a Gilligan's Island Sell Setup and a New 52 Week High.
$KALV's 50-day Moving Average broke above its 200-day Moving Average on September 23, 2020.

Generated by AI

Community

Of the messages about KALV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	28.57%	26.67%	76.04%	21.42%
Newcomers	71.43%	73.33%	23.96%	78.58%

Regulars· Apr 29

Chiesi Group is acquiring KalVista Pharmaceuticals for $27 per share, representing an equity consideration of approximately $1.9 billion.
The acquisition adds to Chiesi's rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening its position in this area.
KalVista's hereditary angioedema pipeline is a key driver of the acquisition, with Chiesi looking to expand its global rare disease portfolio.

Newcomers· Apr 30

The acquisition of KalVista Pharmaceuticals by Chiesi Group is expected to be completed at a 40% premium, providing a clean cash exit for shareholders.
The deal removes uncertainty around KalVista's pipeline, and the company's stock has responded positively, rising 39% after the announcement.
KalVista's pipeline has shown promise, with its treatment for hereditary angioedema (HAE) already capturing 20% of the market in its first year of launch.

Generated by AI

News

Monopar adds commercial leaders ahead of drug filing

2mo agoInvesting.com

Also Discussed

Investors talking about KALV also mention

#	Name	Attention
1	ALBO - Albireo Pharma, Inc.	——
2	Nuvation Bio Inc.NUVB	0%0
3	Pharvaris N.V. Ordinary SharesPHVS	0%0
4	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
5	UroGen Pharma Ltd.URGN	0%new
6	Syndax Pharmaceuticals, Inc.SNDX	0%+0
7	Palvella Therapeutics, Inc.PVLA	0%new
8	argenx SE American Depositary ReceiptARGX	0%0
9	Grace Therapeutics, Inc.GRCE	0%new
10	Orla Mining Ltd.ORLA	0%0